INTRODUCTION
NSCLC, squamous, lung cancer
LUNG CANCER, DISEASE PROGRESSION, SECONDARY, NSCLC
Patients diagnosed with advanced non‐small cell lung cancer (NSCLC) at Stage IIIB and Stage IV have a relatively poor overall prognosis, with 5‐year survival rates of less than 5% and 2%, respectively.Treatment with docetaxel, which has been considered the conventional approach of treating patients who have progressed after a platinum‐based regimen, has not produced significant benefits in HRQoL via reduction in symptom burden.Previous clinical studies have shown that patients with advanced squamous (sq‐) and non‐squamous (nsq‐) NSCLC who were administered tislelizumab in combination with chemotherapy have experienced clinical benefits compared to those who received chemotherapy alone.The RATIONALE 303 (NCT03358875) study was a Phase 3, randomized, open‐label, multicenter clinical trial that examined the effectiveness and safety of tislelizumab compared to docetaxel for NSCLC patients who had experienced disease progression after a previous treatment involving a platinum‐containing regimen.The assessment of HRQoL using patient‐reported outcome (PRO) was a prespecified secondary objective in RATIONALE 303. The current analysis evaluated HRQoL and changes in patient‐reported lung cancer symptoms in patients treated with tislelizumab compared with docetaxel in patients with NSCLC who had experienced disease progression following a prior chemotherapy regimen containing platinum.